About Drugs in Context

Drugs in Context is an open access, peer-reviewed, continuous publication of international standing. It is a member of the Directory of Open Access Journals (https://doaj.org/). It is listed on PubMed and all articles are free-to-view/download immediately on PubMed Central.

Latest rankings (SJR/Scimago 2019): equivalent Impact Factor = 3.56. Q2 title; H index = 15; SJR = 0.848. Ranked 15 of 80 open access pharmacology journals worldwide (based on eIF). Ranked 71 of 326 of all pharmacology journals worldwide (based on eIF).

Articles: we publish high-quality, peer-reviewed original research papers and topical review articles covering the latest evidence and innovations in drug treatment across all therapeutic areas. Other article types are considered.

Peer review: we conduct single-blind external peer review on all manuscripts with comments from at least two peer reviewers. Our aim is to obtain a first editorial decision within 3 weeks of manuscript submission and online publication within 3 weeks of acceptance.

Submit your manuscript: check the 'SUBMISSION' page for full instructions. Submit your manuscript via Manuscript Manager.

Latest Article

Kawasaki disease in siblings and a review of drug treatment

Steven King-fan Loo MBChB, FRCP, Kam Lun Hon MBBS, MD, FAAP, FCCM, Alexander KC Leung MBBS, FRCPC, FRCP (UK & Irel), FRCPCH, FAAP, Tak Cheung Yung MBBS, MRCPCH, Man Ching Yam MBChB, MRCPCH

Articles 2020

Efficacy and safety of photodynamic therapy with RLP068 for diabetic foot ulcers: a review of the literature and clinical experience

Felicia Pantò MD, Liboria Adamo BSc, Carla Giordano MD, Carmelo Licciardello MD

Management of type 2 diabetes: consensus of diabetes organizations

Elaena Quattrocchi BS, PharmD, FASHP, CDE, Tamara Goldberg BS, PharmD, BCPS, Nino Marzella BS, MS, PharmD

Efficacy and safety of a GABAergic drug (Gamalate® B6): effects on behavior and cognition in young adults with borderline-to-mild intellectual developmental disabilities and ADHD

Ramón Novell MD, Susanna Esteba-Castillo PhD, Emili Rodriguez PhD

Thyrotoxicosis after massive triiodothyronine (LT3) overdose: a coast-to-coast case series and review

Zhiheng H He MD, PhD, Yan Li MD, Nitin Trivedi MD, Sabrina Gill MD, James V Hennessey MD

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies

Sonam Puri MD, Michael Shafique MD